[
    [
        {
            "time": "2018-01-01",
            "original_text": "How Bristol-Myers Squibb’s Oncology Drugs Performed in 4Q17",
            "features": {
                "keywords": [
                    "Bristol-Myers Squibb",
                    "Oncology Drugs",
                    "4Q17"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Bristol-Myers Squibb’s Oncology Drugs Performed in 4Q17",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "A Look at Bristol-Myers Squibb’s 4Q17 Revenue",
            "features": {
                "keywords": [
                    "Bristol-Myers Squibb",
                    "Revenue",
                    "4Q17"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Look at Bristol-Myers Squibb’s 4Q17 Revenue",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "How Novartis’s Oncology Segment Drugs Are Performing",
            "features": {
                "keywords": [
                    "Novartis",
                    "Oncology Segment",
                    "Drugs"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Novartis’s Oncology Segment Drugs Are Performing",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "Bristol-Myers Squibb’s Valuation in March 2018",
            "features": {
                "keywords": [
                    "Bristol-Myers Squibb",
                    "Valuation",
                    "March 2018"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Bristol-Myers Squibb’s Valuation in March 2018",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy",
            "features": {
                "keywords": [
                    "FDA",
                    "Bristol-Myers",
                    "Colorectal Cancer",
                    "Combo Therapy"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "3 Biotechs That Could Get Big Boosts in April",
            "features": {
                "keywords": [
                    "Biotechs",
                    "Big Boosts",
                    "April"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Biotechs That Could Get Big Boosts in April",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Biotech Stocks Facing FDA Decision In April",
            "features": {
                "keywords": [
                    "Biotech Stocks",
                    "FDA Decision",
                    "April"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biotech Stocks Facing FDA Decision In April",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]